Drug Search Results
More Filters [+]

SHP-639

Alternative Names: shp-639, shp639, shp 639
Latest Update: 2019-08-07
Latest Update Note: Clinical Trial Update

Product Description

TAK-639 is a topical, nine-amino acid, synthetic, C-type natriuretic peptide analog in Phase 1 development for the treatment of ocular hypertension (OHT) and primary open-angle glaucoma (POAG). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32256046/)

Mechanisms of Action: NPRB Agonist

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SHP-639

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Hypertension|Glaucoma, Open-Angle

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SHP639-101

P1

Completed

Glaucoma, Open-Angle|Hypertension

2018-05-30

Recent News Events

Date

Type

Title